4,5,6,7-Tetrahydrobenzothiophen | 6435-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 4,5,6,7-Tetrahydrobenzothiophen
• 英文别名: 4,5,6,7-tetrahydro-2-benzothiophene
• CAS: 6435-76-3
• 化学式: C₈H₁₀S
• 分子量: 138.233
• InChiKey: VGZXFRBGPCUTHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4,5,6,7-Tetrahydrobenzothiophen 在 正丁基锂 、 二氧化硫 作用下， 生成 Lithium; 4,5,6,7-tetrahydro-benzo[c]thiophene-1-sulfinate
  参考文献：
  名称：

  Sulfonylureas: a new class of cancer chemotherapeutic agents

  摘要：

  This study summarizes the antitumor properties of a number of sulofenur thiophene analogs against subcutaneously implanted 6C3HED lymphosarcoma with structural modification of the aryl moiety of the sulfonamide portion of the diarylsulfonylureas. The spectrum of activity of N-(p-chlorophenyl)-N'-[(5-methoxy-2-thienyl)sulfonyl]urea in the HXGC3, VRC5, CX-1, and LX-1 cell lines is also presented.

  DOI：

  10.1021/jm00094a013
• 作为产物：
  描述：

  Spiro 以10%的产率得到
  参考文献：
  名称：

  PRAEFCKE K.; WEICHSEL CH., LIEBIGS ANN. CHEM., 1980, NO 10, 1604-1619

  摘要：

  DOI：

文献信息

• [EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET PROCÉDÉ D'UTILISATION CORRESPONDANT
  申请人：SUNOVION PHARMACEUTICALS INC

  公开号：WO2013119895A1

  公开（公告）日：2013-08-15

  Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

  本文提供了噻吩化合物，其合成方法，包含这些化合物的药物组合物，以及它们的使用方法。本文提供的化合物可用于治疗、预防和/或管理各种神经系统疾病，包括但不限于精神病和精神分裂症。
• 2,6-DIOXASPIRO [4,5] DECANE DERIVATIVES AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATIONS THEREOF
  申请人：SHANDONG LUYE PHARMACEUTICAL CO., LTD.

  公开号：US20200255444A1

  公开（公告）日：2020-08-13

  The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor p agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.

  本发明涉及一系列2,6-二氧杂螺[4,5]癸烷衍生物及其在制备阿片受体P激动剂相关药物中的应用；特别涉及式(I)所示的衍生物化合物，其互变异构体或其药学上可接受的组合物。
• Thienylalanine derivatives as inhibitors of cell adhesion
  申请人：——

  公开号：US20030105080A1

  公开（公告）日：2003-06-05

  The present invention relates to compounds of formula (I), in which A, B, X, Y, R 1 , R 2 , R 3 and n have the meanings indicated in the claims. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention fruthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中A、B、X、Y、R1、R2、R3和n具有所述索引中指示的含义。式（I）的化合物是有价值的药理活性化合物。它们是vitronectin受体拮抗剂和细胞黏附抑制剂，适用于基于细胞-细胞或细胞-基质相互作用过程中vitronectin受体和它们的配体之间相互作用的疾病的治疗和预防，或者可以通过影响这些相互作用来预防、缓解或治愈这些疾病。例如，它们可以应用于通过抑制骨吸收细胞破骨细胞来治疗和预防骨质疏松症，或者用于抑制不良血管生成或血管平滑肌细胞增殖。此外，本发明还涉及式（I）的化合物的制备过程，它们的使用，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
  申请人：Olson Maria Lisa

  公开号：US20050107350A1

  公开（公告）日：2005-05-19

  The present invention describes a novel method for preventing or treating bone disorders and bone disorder-related complications in a subject involving a monotherapy with a Cox-2 inhibitor or a combination therapy with a Cox-2 inhibitor and a bone disorder treatment agent. Also described are therapeutic compositions comprising a Cox-2 inhibitor and a bone disorder treatment agent. Pharmaceutical compositions and kits for implementing the present method are also described.

  本发明描述了一种新的方法，用于预防或治疗受体中的骨骼疾病和与骨骼疾病相关的并发症，包括单独使用Cox-2抑制剂或与骨骼疾病治疗剂的联合治疗。还描述了含有Cox-2抑制剂和骨骼疾病治疗剂的治疗组合物。还描述了用于实施本方法的药物组合物和工具包。
• 1,1-Disubstituted cycloalkyl derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20040254158A1

  公开（公告）日：2004-12-16

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药学上可接受的盐形式，这些化合物可用作因子Xa的抑制剂。